Related Experiment Videos
Coronary reperfusion for the treatment of acute myocardial infarction: postischemic ventricular dysfunction
Insights
Fibrinolytic therapy can reduce myocardial infarct size in acute myocardial infarction. However, focus clinical trials on long-term cardiac function changes, not short-term, due to the stunned myocardium phenomenon.
Area of Science:
- Cardiology
- Cardiovascular Research
- Regenerative Medicine
Background:
- Acute myocardial infarction (AMI) treatment is evolving with interest in coronary reperfusion.
- Fibrinolytic therapy offers potential for reducing infarct size.
- Reperfusion may lead to delayed recovery of cardiac function and metabolism, known as stunned myocardium.
Purpose of the Study:
- To evaluate the impact of coronary reperfusion on myocardial infarct size and subsequent cardiac function.
- To investigate the phenomenon of stunned myocardium following reperfusion therapy for AMI.
- To guide clinical trial design for reperfusion therapies in AMI.
Main Methods:
- Review of experimental studies on coronary reperfusion and its effects.
- Analysis of infarct size reduction following fibrinolytic therapy.
- Assessment of postischemic cardiac function, high energy phosphate metabolism, and ultrastructure.
Main Results:
- Coronary reperfusion, particularly via fibrinolytic therapy, can reduce myocardial infarct size.
- Salvaged myocardial tissue may exhibit delayed recovery of function, metabolism, and ultrastructure (stunned myocardium).
- Hemorrhage in reperfused infarcts is localized to necrotic areas and does not worsen necrosis extent.
Conclusions:
- While reperfusion reduces infarct size, the stunned myocardium phenomenon necessitates careful evaluation of recovery.
- Clinical trials for AMI reperfusion therapy should prioritize assessment of long-term cardiac function improvements.
- Focusing on long-term outcomes will provide a more accurate measure of therapeutic benefit for acute myocardial infarction.
Abstract:
There has been recent interest in treating acute myocardial infarction with coronary reperfusion by fibrinolytic therapy. Experimental studies have shown that myocardial infarct size can be reduced by coronary reperfusion. However, return of cardiac function, high energy phosphate metabolism, and cardiac ultrastructure may be delayed within tissue which is salvaged by coronary reperfusion. This postischemic ventricular dysfunction is transient and has been termed the 'stunned myocardium' phenomenon. Although reperfused infarcts are hemorrhagic, the hemorrhage is confined well within tissue which is already necrotic and does not appear to exacerbate the extent of necrosis. Clinical trials designed to assess the benefits of reperfusion for the therapy of acute myocardial infarction should concentrate on long-term rather than short-term changes in cardiac function.